Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 13,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Healthy, Skin Ulcer
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 999 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Cancer
Interventions: physiologic testing, screening questionnaire administration, breast imaging study, radiomammography, study of high risk factors; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 40 Years and older · Female only
Enrollment: 2,201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 8
States / cities: Cleveland, Ohio • Mayfield Heights, Ohio • Mentor, Ohio + 5 more

Conditions: Atopic Dermatitis
Interventions: PR022; Drug
Lead sponsor: Realm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Triple Negative Breast Cancer
Interventions: Cyclophosphamide, Placebo, Doxorubicin, Paclitaxel, Carboplatin, Veliparib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 634 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 61
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 47 more

Conditions: Triple Negative Breast Cancer
Interventions: Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Personalized cancer vaccine (PCV), AB248, pVAC tools neoantigen prediction algorithm, poly-ICLC; Drug · Biological · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Warts
Interventions: VBP-245, Placebo Gel (no Povidone-Iodine); Drug
Lead sponsor: Veloce BioPharma LLC; Industry
Eligibility: 8 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Hunt Valley, Maryland • Plymouth Meeting, Pennsylvania • Sugarloaf, Pennsylvania + 4 more

Conditions: Condyloma
Interventions: Leukocyte Interleukin, Injection 200IU, Leukocyte Interleukin, injection 400IU; Drug
Lead sponsor: United States Naval Medical Center, San Diego; Federal
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Basal Cell Carcinoma, Melanoma, Non-Malignant Skin Disorders, Squamous Cell Carcinoma
Interventions: Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength); Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: questionnaire administration, survey administration, quality-of-life assessment; Other · Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Foot Ulcer, Diabetic
Interventions: No intervention; Other
Lead sponsor: Podimetrics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Breast Cancer, Breast Neoplasm
Interventions: Pazopanib; Drug
Lead sponsor: Hope Rugo, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Angioedema
Interventions: Lanadelumab; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 12 more

Conditions: Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Interventions: Apremilast; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Portland, Oregon + 1 more

Conditions: Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
Interventions: CMP-001, Nivolumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 16 more

Conditions: Lower Extremity or Diabetic Foot Ulcers, Bacterial Infection
Interventions: Larval Debridement Therapy, Bedside Sharp Debridement; Device · Procedure
Lead sponsor: North Florida Foundation for Research and Education; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Actinic Keratosis
Interventions: PEP005 (ingenol mebutate) Gel; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: carboxyamidotriazole, paclitaxel; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2006
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Fulvestrant, Laboratory Biomarker Analysis, Palbociclib, Questionnaire Administration, Aromatase Inhibitors; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: Edgewood, Kentucky • Cleveland, Ohio • Columbus, Ohio

Conditions: Diabetic Foot Ulcer
Interventions: Dual-layer perinatal tissue allograft, Three-layer fenestrated perinatal tissue allograft, Standard of care; Other
Lead sponsor: Samaritan Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Monroe, North Carolina

Conditions: Breast Cancer
Interventions: filgrastim, trastuzumab, docetaxel, vinorelbine; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 145
States / cities: Mobile, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 89 more

Conditions: Breast Cancer
Interventions: Text message reminder; Behavioral
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 724 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 204
States / cities: Anchorage, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 144 more

Conditions: Rosacea
Interventions: systemic and local stressors; Other
Lead sponsor: Kristen Metzler-Wilson; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Indianapolis, Indiana • Lexington, Kentucky

Conditions: Breast Cancer, Quality of Life
Interventions: Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene; Radiation · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 65 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 64
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 54 more

Search by objective public record fields.

Pathophysiology of Chronic Wounds

Changes in Breast Density and Breast Cancer Risk in Women With Breast Cancer and in Healthy Women

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer

Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients

Topical 2% Povidone-Iodine Gel in Verruca Vulgaris

Safety Study of Multikine in the Treatment of Perianal Warts

Multi-Wavelength and Coherence Confocal Reflectance Microscopy of Pigmented and Non-Pigmented Lesions on the Skin In-Vivo

Self-Care for Lymphedema in Patients With Breast Cancer

Approaches to Foot Complication Prevention: A Survey of Diabetes Educators

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

Evaluating the Efficacy of Perinatal Membrane Allografts in Addition to the Standard of Care for the Treatment of Non-healing Diabetic Foot Ulcers.

S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer

S1105: Text-Messaging Intervention to Reduce Early Discontinuation of AI Therapy in Women With Early-Stage Breast Cancer

Role of the Sympathetic Nervous System in Rosacea

Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)